RYH0 Stock Overview
A clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sareum Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.27 |
| 52 Week High | UK£0.70 |
| 52 Week Low | UK£0.11 |
| Beta | -0.98 |
| 11 Month Change | 8.87% |
| 3 Month Change | -14.01% |
| 1 Year Change | -59.40% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| RYH0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.8% | -1.2% | -0.02% |
| 1Y | -59.4% | -20.1% | 8.2% |
Return vs Industry: RYH0 underperformed the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: RYH0 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| RYH0 volatility | |
|---|---|
| RYH0 Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RYH0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RYH0's weekly volatility has decreased from 18% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 5 | n/a | www.sareum.com |
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases.
Sareum Holdings plc Fundamentals Summary
| RYH0 fundamental statistics | |
|---|---|
| Market cap | €39.78m |
| Earnings (TTM) | -€4.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.7x
P/E RatioIs RYH0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RYH0 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£3.42m |
| Earnings | -UK£3.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.027 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RYH0 perform over the long term?
See historical performance and comparison